Health Condition 1: L210- Seborrhea capitis
Conditions
Interventions
Intervention1: M6D Shampoo: Water, Sodium Laureth Sulfate,
Sodium Lauryl Sulfate, Sodium Chloride, Sodium Xylenesulfonate, Cocamidopropyl Betaine, Sodium Citrate, Fragrance, Piroctone Olamine, Me
Sponsors
CavinKare Private Limited., India
Eligibility
Inclusion criteria
Inclusion criteria: 1 Male and female participants aged between 18 and 45 years. 2. A total Participants with moderate-to-severe dandruff will be enrolled in a ratio of 40 (moderate) :60 (severe)/ 30 (moderate) :70 (severe). 3. Participants who are committed not to use medicated/non medicated shampoos/soaps (including soaps containing antibacterial/antifungal agents) or any other antidandruff treatment/hair products (including prescription and non- prescription medications such as hair oil, conditioners) for the entire duration of the study. 4. Participants will be asked to use the shampoo 2 times a week and accepting to follow this procedure during the whole study period. 5. Participants who did not participated in any other clinical trial during the past 3 months.
Exclusion criteria
Exclusion criteria: 1.Scalp Psoriasis. 2. Participants who underwent any type of hair procedures within the past 2 weeks or during the study. 3. Participants with immediate life-threatening diseases such as pre- existing cardiovascular, liver or neoplastic disease. 4. Participants undergoing treatment for immune-compromised conditions/psychiatric illness. 5. Participants with any other co- morbid conditions like diabetes that can affect the study outcome. 6. Pregnant or lactating women 7. Hypersensitivity to any of the components of the test formulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Total Dandruff Severity Score (TDSS) 2. Hair performance (Investigator & participant Assessment) 3. Global Improvement Assessment 4. Scalp Condition Scoring (Dermatologist Assessment) 5. To assess DLQI (Dermatology Life Quality Index) 6. Assessment of recurrence at the end of the study.Timepoint: Visit 1 (Day 0 - D), Visit 2 (D+7), Visit 3 (D+8), Visit 4 (D+9), Visit 5 (D+14), Visit 6 (D+21) and Visit 7 (D+35) | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor for any adverse events during the study period.Timepoint: Baseline upto 6 weeks | — |
Countries
India
Contacts
Public ContactDr Gayathri Sivakumar
DK Elite Health Care Centre
Outcome results
None listed